August 2, 2017 Off

Orexo’s Zubsolv tablet on the CVS Caremark formulary

By Dino Mustafić

Orexo AB said on Wednesday that Zubsolv tablet’s position has changed from excluded from reimbursement to reimbursed as a preferred product. Zubsolv is buprenorphine and naloxone sublingual tablet (CIII) managed care formulary position with CVS Caremark for patients suffering from opioid dependence. 

August 2, 2017 Off

FDA OK’s Gilead Sciences’s hepatitis C drug

By Dino Mustafić

The U.S. Food and Drug Administration (FDA) has approved updated labeling for Gilead Sciences’s Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.

August 2, 2017 Off

Arix supports Amplyx Pharmaceuticals with $67

By Dino Mustafić

Arix Bioscience has acquired an interest in Amplyx Pharmaceuticals – San Diego-based Amplyx is focused on developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections – as part of an oversubscribed $67 million Series C financing round. 

August 2, 2017 Off

FDA accepts AstraZeneca’s drug for multiple B-cell and other cancers.

By Dino Mustafić

The US Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for acalabrutinib, a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor, developed by AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma. This potential new medicine is in development for the treatment of multiple B-cell and other cancers.